Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma

Clin Immunol. 2023 Apr:249:109290. doi: 10.1016/j.clim.2023.109290. Epub 2023 Mar 15.

Abstract

The value of peripheral blood lymphocyte subpopulations in predicting responses to lenvatinib combination with programmed death-1 (PD-1) inhibitors in unresectable hepatocellular carcinoma (HCC) was investigated. Fifteen patients received objective responses (OR) and sixteen patients had non-objective responses (NOR) were analyzed. The counts of peripheral blood lymphocyte subpopulations from patients were measured before treatment, second (at week 3), and third doses (at week 6) of the PD-1 inhibitor administration, and correlated with responses. Helper T (Th) cells and natural killers (NK) cells were more abundant in the OR group and found to be important predictors of OR in a stepwise multivariate logistic regression analysis. These cutoff values of Th and NK cells could help to distinguish OR from NOR cases accurately and provide clinical benefits.

Keywords: Hepatocellular carcinoma; Lenvatinib; Lymphocyte; PD-1 inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Killer Cells, Natural
  • Liver Neoplasms* / drug therapy

Substances

  • lenvatinib
  • Immune Checkpoint Inhibitors